CSF2 and metastatic melanoma: Oncolytic viruses, which specifically target and lyse cancer cells, have entered clinical trials, and T-VEC, a herpes virus also carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), is approved for the local treatment of unresectable metastatic melanoma (36, 37).